Cargando…
Recent Studies on Ponatinib in Cancers Other Than Chronic Myeloid Leukemia
Ponatinib is a third line drug for the treatment of chronic myeloid leukemia patients, especially those that develop the gatekeeper mutation T315I, which is resistant to the first and the second line drugs imatinib, nilotinib, dasatinib and bosutinib. The compound was first identified as a pan Bcr-A...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6267038/ https://www.ncbi.nlm.nih.gov/pubmed/30423915 http://dx.doi.org/10.3390/cancers10110430 |